showed that an analog of the pan glutaminase inhibitor, 6-diazo-5-oxo-L-norleucine (DON), not only inhibited glutamine metabolism but also inhibited glycolysis and related pathways, thus disabling the Warburg effect and significantly reducing tumor growth (Leone et al., 2019). The gene discussed is GLS; the disease is neoplasm.